- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE presents newly approved molecular agent
GE Healthcare debuted at RSNA 2008 a recently FDA-approved molecular imaging agent that homes in on rare neuroendocrine tumors. The new agent, technically known as Iobenguane I 123 Injection, was approved earlier this year for use in diagnosis and during follow-up of patients with these tumors, if relapse or recurrence is suspected, according to GE, which began shipping the product in late October.
GE Healthcare debuted at RSNA 2008 a recently FDA-approved molecular imaging agent that homes in on rare neuroendocrine tumors. The new agent, technically known as Iobenguane I 123 Injection, was approved earlier this year for use in diagnosis and during follow-up of patients with these tumors, if relapse or recurrence is suspected, according to GE, which began shipping the product in late October.
The agent promises to have a major impact on the diagnosis of children with neuroblastoma, the most common extracranial solid tumor of young children up to five years of age. It will also provide reliable imaging data to aid in identifying primary and metastatic pheochromocytoma, a predominantly adult tumor that often presents diagnostic challenges. These two diseases can be difficult to detect at an early stage because symptoms may be nonspecific when the tumors are small.
GE Healthcare began developing AdreView in 2004. It was granted orphan drug status by the FDA in December 2006. In May 2008, AdreView received priority review status from the FDA.
AI Facilitates Nearly 83 Percent Improvement in Turnaround Time for Fracture X-Rays
December 19th 2023In addition to offering a 98.5 percent sensitivity rate in diagnosing fractures on X-ray, an emerging artificial intelligence (AI) software reportedly helped reduce mean turnaround time on X-ray fracture diagnosis from 48 hours to 8.3 hours, according to new research presented at the Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
